Change 5-day change 1-year change 3-year change Capi.($)
+5.60%-6.13% - - 303M
-0.18%+4.35%+4.23%+30.02% 47.86B
-0.81%-0.22%+43.86%+32.53% 44.46B
-1.01%+4.73%+10.78%+91.49% 41.85B
-0.71%-2.87%+330.49%+545.08% 41.34B
-0.62%-0.06%+10.15%+46.02% 30.04B
-1.79%+0.31%+24.63%+152.69% 17.59B
-5.08%-9.22% - - 15.6B
-3.55%+1.95%+21.97%+39.13% 15.69B
-1.45%+9.15%-9.22% - 13.93B
Average -0.98%+2.66%+54.61%+133.85% 29.82B
Weighted average by Cap. -1.22%+1.88%+68.13%+142.06%
Logo OvaScience Inc
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Employees
-